EP Patent

EP3600322A1 — Nintedanib for use in methods for the treatment of muscular dystrophy

Assigned to Boehringer Ingelheim International GmbH · Expires 2020-02-05 · 6y expired

What this patent protects

Tyrosine kinase inhibitors, selected from nintedanib and pharmaceutically acceptable salts thereof, can be used in methods for the treatment of muscular dystrophy.

USPTO Abstract

Tyrosine kinase inhibitors, selected from nintedanib and pharmaceutically acceptable salts thereof, can be used in methods for the treatment of muscular dystrophy.

Drugs covered by this patent

Patent Metadata

Patent number
EP3600322A1
Jurisdiction
EP
Classification
—
Expires
2020-02-05
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.